AtriCure, Inc. (ATRC) is a prominent medical device company that provides innovative solutions designed to decrease the global epidemic of atrial fibrillation (AFib) and related conditions. The company is headquartered in Mason, Ohio, USA, and operates globally, providing relief and improved health to patients all over the world. AFib is a common cardiac disorder that increases the risk of stroke and cardiovascular diseases.
AtriCure, Inc.'s key product line includes ablation devices, a full solution for the surgical treatment of Afib and left atrial appendage management (LAAM). Their ablation technologies work by creating a line of scar tissue to block abnormal electric signals in the heart, restoring a regular heartbeat. The company's AtriClip Left Atrial Appendage Exclusion System product constitutes the most widely sold device worldwide for left atrial appendage management.
Established in 2000, AtriCure, Inc. has dedicated over two decades to developing and bringing to market a comprehensive suite of therapies aimed at rectifying the significant health issues attributed to AFib and other cardiac disorders. The company's commitment to research and education in the field of atrial fibrillation has set them apart as industry leaders.
In addition to technology, AtriCure, Inc. has made significant contributions to the field of education and training for healthcare professionals to create a broader understanding of the sources of AFib, as well as the surgical and hybrid procedural solutions.
As of now, over 200,000 patients with AFib have been treated with AtriCure technologies. Financially, AtriCure is a publicly traded company, listed on the NASDAQ Stock Market under the ticker ATRC.
In the face of a global epidemic of AFib, AtriCure, Inc. continues to innovate and contribute to enhanced patient care. They are fully committed to invest in clinical science, education, and training to ensure safe and effective treatment paving the way towards improved healthcare standards worldwide. Maintaining a steadfast dedication to quality, the company operates under a strict quality-focused system that meets the stringent needs of their medical device customers.
In conclusion, AtriCure, Inc. stands out as a pioneer, innovator, and leading-edge company in the fight against cardiac disorders such as AFib, enhancing the lives of patients and creating sustainable value for healthcare providers worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
AtriCure (ATRC) has seen a strong 73.5% share price increase over the past year, leading to a valuation where its P/S ratio of 5.4x is higher than the Medical Equipment industry average. Simply Wall St's analysis suggests the stock might be rich against its sales base, indicating a premium is being paid for its revenues. The article presents both bull and bear cases, with analysts debating whether current catalysts justify the valuation or if expectations are already too high.
An insider at Atricure (NASDAQ: ATRC) has sold shares valued at $271,140, as disclosed in a recent SEC filing. This transaction follows other insider sales reported in recent months, alongside news of AtriCure, Inc. being added to various S&P indices and analyst rating adjustments. The article also provides a company profile, financial data, and analyst consensus for AtriCure, Inc.
AtriCure (ATRC) has seen a significant share price surge, up 66.13% over the past year, prompting questions about its valuation. Simply Wall St's analysis suggests the stock is currently 16% overvalued, with a fair value estimated at $51.67 compared to its recent close of around $59.96. The company's rapid revenue growth from innovative medical devices is highlighted, but potential risks such as competition in minimally invasive cardiac procedures are also noted.
Regina E. Groves, a Board Member at AtriCure (NASDAQ: ATRC), sold 5,313 shares of the company's stock for a total transaction value of $288,070, as disclosed in a recent SEC filing. AtriCure specializes in surgical treatments for atrial fibrillation and pain management, and the article provides a financial overview highlighting its revenue growth, gross margin, but also its below-average EPS and high valuation ratios. Insider transactions like this sale offer insights into a company's prospects, though a sale doesn't necessarily indicate a negative outlook.
Regina Groves, a Director at AtriCure Inc (ATRC), sold 5,313 shares of the company on September 11, 2026, with shares trading at $54.22. This transaction is part of a broader pattern of insider selling at AtriCure, which contrasts with some institutional investors accumulating shares. GuruFocus's valuation indicates the stock is "Significantly Overvalued" at a price-to-GF-Value ratio of 1.36 and a high P/E ratio of 265.67.
AtriCure Director Regina E. Groves sold 5,313 shares of AtriCure (NASDAQ: ATRC) at $54.22 each on September 11, 2026. This sale represented approximately 13.3% of her previous holdings, leaving her with 34,546 shares. The transaction was disclosed through regulatory filings, providing insight into insider activity.
AtriCure's CTO, Salvatore Privitera, sold 3,657 shares for approximately $201,000, while still retaining a significant equity position of 147,000 shares valued at $7.9 million. Despite this sale, AtriCure's stock has performed strongly, rising 55.5% over the past year, reflecting growth in the cardiac surgery and arrhythmia treatment sectors. Analysts, however, project a cautious outlook with a median one-year price target of $52, suggesting a potential 4.6% downside from the current price.
This article analyzes Atricure Inc. (ATRC) for its impact on rotational strategy timing, highlighting strong near-term and mid-term sentiment which could lead to long-term gains. It provides specific AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report suggests compelling upside potential due to the absence of clear resistance above the current price.